Aegirbio AB, Interim report Jan - jun 2020
SUMMARY OF THE QUARTERLY REPORT
"The Company" and "Aegirbio" refer to AegirBio AB (publ), reg.no. 559222-2953. No comparative amounts are presented for the period as the company was established on 2019-10-14.
FIRST HALF OF THE YEAR (2020-01-01 – 2020-06-30)
- Revenue amounted to KSEK 14.
- Profit before taxes amounted to KSEK -5,506.
- Earnings per share* amounted to SEK -0.60.
- Solidity** amounted to 73 percent as of June 30, 2020.
SECOND QUARTER (2020-04-01 – 2020-06-30)
- Revenue amounted to KSEK 14.
- Profit before taxes amounted to KSEK -4,223.
- Earnings per share* amounted to SEK -0.46.
* Earnings per share: Profit/loss for the period divided by 9,160,878 shares, which as of 2020-06-30 is the registered number of shares.
** Solidity: Equity divided by total capital.
Amounts in brackets: Corresponding period in the previous year.
SIGNIFICANT EVENTS DURING THE SECOND QUARTER OF 2020
On April 9, the company announces that Aegirbio's technology opens up new possibilities in the control of immunity after infection or vaccination against viruses. The Veritope molecules that are a central part of Aegirbio's operations within precise dosing of biological drugs can be used as a basis for testing the immunity of patients (antibodies). One example is immunity to coronavirus.
On April 14, the company announces that it has completed its first sale.
On April 29, Aegirbio announces its intent to apply for listing on the Nasdaq First North Growth Market.
On May 8, it is announced that Aegirbio has attracted a lot of attention on the company’s COVID-19 tests. The U.S. company Abreos Biosciences, which owns Aegirbio AB jointly with LifeAssays AB, has received considerable attention in the BioWorld magazine with a project aiming to create tests for specific COVID-19 antibodies. Aegirbio's partner is described as a company with novel and interesting technology that can create tests with far better performance than the ones on the market today. With Aegirbio’s MagniaReader platform, health centres and similar settings would be able to offer quantitative testing with performance equivalent to the central laboratory's.
On May 29, the Company publishes a growth prospectus regarding an issue of units on the Nasdaq First North Growth Market. In conjunction with the listing, as mandated by the Annual General Meeting on February 3, 2020, the Swedish public and institutional investors are offered to subscribe for no more than 2,000,000 units in the Company. Each Unit consists of (1) share and (1) subscription warrant of Series TO1 (”the Offering”). If the Offering attracts very strong interest, the Board of Directors has the option to issue no more than 300,000 additional units in a so-called overallotment issue. The subscription period to participate in the Offering runs from June 1 to June 15 2020 inclusive, and the preliminary first day of trading is June 26, 2020.
On June 8, the Company announces that it will present at the “Småbolagsdagarna 2020” event.
On June 16, the Company announces that the issue of units has been massively oversubscribed. The MSEK 15 Offering was subscribed to approximately MSEK 46, corresponding to a subscription rate of approximately 307 percent. The Board of DIrectors of Aegirbio therefore decided to utilize the overallotment option of 300,000 units. Through the Offering and the overallotment option, Aegirbio is provided about 1,100 new shareholders in total.
On June 22, it is announced that Aegirbio has been approved for listing on the Nasdaq First North Growth Market. Trading of shares and warrants in Aegirbio will commence on Friday, June 26, 2020. The Company's share is traded under the AEGIR ticker and the Company’s warrant under the AEGIR TO1 ticker.
On June 26, the Company announces that trading of shares in Aegirbio AB has commenced on Nasdaq First North Growth Market.
SIGNIFICANT EVENTS AFTER THE PERIOD
On July 27, the Company announces the launch of a new strategy, “From Precision Diagnostics to Precision Medication”, where the long-term goal is to have the Company admitted for trading on a larger Exchange.
On August 4, the Company announces that the exercise of TO1 warrants has resulted in approximately MSEK 3.6 in proceeds.
CEO MARTIN LINDE
It is with great joy and pride that I look back upon the early days of the company. We can conclude that the first half of the year has been full of successes, but it also contained a few concerns in the form of a corona pandemic and the effect that it had on our activities.
I am pleased to note the confidence placed in us by our shareholders, who oversubscribed the issue by 307 percent; the subsequent rise of the share price to the current levels is both flattering and a challenging call to action.
We have made giant strides forward over the course of the first half of the year, and it is encouraging to see that we have successfully concluded our first sale, to Dr. John Foley at the Rocky Mountain MS Clinic in the United States. We have, in other words, ensured that we have a marketable product – the moNATor, for patients suffering from MS that receive treatment with the drug Tysabri – and that we have the entire framework in place including product, logistics and analysis. This is excellent and fully in line with our plan. Unfortunately, we have in a way been impacted by the corona pandemic since it is currently difficult to gain access to healthcare professionals in the United States – due to the interstate travel ban and the fact that they are fully engaged in combating the pandemic. Nevertheless, we are now well placed to increase our sales during the fall and to intensify the development of new analyses. We have a good pipeline to work with.
If we look at the technology related to Veritope and MagniaReader, our effort to roll out these products, individually as well as in combination, continues as planned. We can see that the market is showing a lot of interest in our products, both in the laboratory solution and the point of care solution. As regards the development of a COVID-19 antibody test, we are still waiting for the NIH to provide its final response while we continue the development effort in order to accelerate the time to market as much as possible.
Following the IPO, the Board of Directors of Aegirbio has opted to update and clarify the Company's strategy. We could broadly sum up the strategy as a focus on building a multi-diagnostic company. This will be achieved through further development of our current technology as well as through acquisitions of companies that complement us. The long-term objective of Aegirbio is to grow the company quickly and then list it on a regulated market abroad within 12-18 months.
The headline target remains to focus on providing benefits for customers and patients. Aegirbio considers that the new strategy will allow the company to complement the existing technology focused on Veritope and MagniaReader, thus strengthening our offer to the market.
To be given the opportunity to lead such a fast-paced company with such vast potential is very inspiring. It is truly exciting that we have found a well-defined niche where we believe our knowledge to be world- leading, and that there are so many smaller and larger companies that consider their technology complementary to ours. There is substantial potential for growth in the company, organically and through complementary acquisitions. We are bound to find resources and companies that will help us reach commercial success with our technology (Veritope+MagnaReader) and create significant shareholder value. Aegirbio is looking towards an extremely exciting future, with regard to the roll-out of the products within the pipeline for precise dosing of biological drugs as well as the possible acquisitions that lie ahead of us this fall.
Martin Linde, CEO of Aegirbio AB
Read the full report in the attached pdf
For further information, please contact:
Martin Linde, CEO, Aegirbio AB
Phone: +46 706730968
Aegirbio is a Swedish diagnostics company offering tests to monitor and optimize the dosing of biological drugs by means of a unique, patented technology platform. Biological therapies is the fastest growing segment of the pharmaceutical industry; a quarter of all drugs are projected to be biological in 2020. At the same time, drug concentrations vary tremendously (up to 100 times) in patients that receive biological drugs in standard doses.
The result of this one size fits all-approach is that patients with low drug concentrations do not respond to treatment while excessive drug concentrations increase the risk of adverse effects in others. The uncertainty surrounding dosing results in overdosing or underdosing in about 55 percent of the cases, which causes unnecessary costs and suboptimal clinical outcomes.
The Company's tests for optimal dosing of biological drugs will be focused on neurological disorders, autoimmune diseases and cancer. In the first quarter of 2020, Aegirbio initiated sales in the U.S. of the MoNATor test for the drug Tysabri, which is used for treatment of the neurological disorder Multiple Sclerosis (MS). Aegirbio’s goal is to launch a total of four tests before 2023. Diagnostics will be offered through laboratory testing as well as in the form of a P.O.C. (Point of Care) test for use in hospitals and health centres. The plan further includes P.O.N. (Point of Need) tests for use at home.
For more information, see Aegirbio's website www.aegirbio.com
The company's Certified Adviser is Eminova Fondkomission AB | 08-684 211 00 | firstname.lastname@example.org
This information is such information that Aegirbio AB is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the care of the above contact person, for publication on August 27, 2020 at 18:10 CET.